Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

Two posters presented at the 2025 European Hematology Association Congress support combination therapy with daratumumab, ...

During a live event, Samuel M. Rubinstein, MD, discussed the outcomes from the KarMMa-3 trial and real-world patients ...

Yelak Biru was diagnosed with multiple myeloma at 25 and given just a few years to live. Thirty years later, he's thriving.

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...

A “Trojan horse” therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world ...

Oral presentation of CARTITUDE-1 study data showcases long-term outcomes after a single infusion of CARVYKTI ® with one-third of patients with relapsed/refractory multiple myeloma progression-free for ...

Get trusted information for every step of your journey. Multiple myeloma can be tricky. That’s because it sometimes has no symptoms. Or the signs look like other illnesses. What causes multiple ...

During a live event, Konstantinos Sdrimas, MD, and community oncologists discussed patient concerns over CAR T-cell therapy ...

Diagnosed with incurable cancer, Jonathan Gluck reveals how two decades of uncertainty taught him to find resilience through ...